FDA considers first CRISPR gene editing treatment that may cure sickle cell | CNN

S age 45 cell a Lakiea Bailey inful and deadly disease with no universally successful treatment.

About 100,000 people in the US are diagnosed with sickle cell and, the Sickle Cell Consortium t’s considered severe disease.

Up until n age 3 he only real treatment has been a stem cell or bone marrow transplant.

The new exa-cel treatment uses CRISP Bailey editi the US Food and Drug Administration’s ause the disease.

Several pane Tuesday ts said they believed the data the companies have submitted for FDA approval were reasonable.

Dr. Scot Wolfe, a temporary voting member of the committee, said he liked that the company promised to monitor patients for 15 years to see if there were any problems down the road.

T Bailey is expect FDA to make a deci Tuesday December 8. FDA tText__NxlGi">October Scot Wolfe FDA December 8 FDA US h one htText__NxlGi">Bauer Bauer CRISPR > Bauer the CNN Health every Tuesday FDA class="summaryFeed_highLightText__NxlGi">Sanjay Gupta The Results Are In weekly Get CNN Health's Wolfe one Wolfe Wolfe Boston Children’s Hospital Dana-Farber/Boston Children’s Cancer Daniel BauerOne 15 years 100 ss="sum just last year ightText__NxlGi">UMass Chan only 45 years l African Americans About 100,000 summaryFeed_hig US ightText__NxlGi">FDA 20,000 _highLightText__NxlGi">FDA FDA U fewer than 20% span class="summaryFeed_highLightText__NxlGi">30 years FDA pan> CRISPR the University of FDA lifornia, Berkeley the Depar CRISPR of Molecular and Cell Biology Fyodor Urnov one aryFeed_highLightText__NxlGi">CRISPR FDA first Stephanie Krogmeier yFeed_highLightText__NxlGi">FDA Vertex Pharmaceuticals Incorporated about two weeksThirty-nine class=" 40 mmaryFeed_highLightText__NxlGi">about four